Aclarion (ACON) Update / Briefing November 23, 2024 07:00 AM ET Speaker0 The during the webcast, you may do so at any point during the presentation by clicking on the Ask Question button on the left of your screen. Type your question into the box and hit submit. I'd now like to turn the floor over to today's host, mister Seth Trayman, executive chairman of Aclarian Incorporated. Sir, the floor is yours. Speaker1 Thank you. Hello, everyone. My name is Jeff Trayman. I'm the executive chairman of Aclarian. A l ...

Summary of Pfizer Inc. Conference Call Company Overview - **Company**: Pfizer Inc. (NYSE:PFE) - **Event**: Jefferies London Healthcare Conference - **Date**: November 20, 2024 Key Points Industry and Market Context - Pfizer is focused on execution and enhancing its Oncology franchise while optimizing its cost structure post-COVID, with a revenue base of approximately $60 billion [4][3] - The company is navigating changes in the U.S. healthcare administration, which may have both positive and negative impacts on its business [6][7][8] Financial Performance and Guidance - Pfizer's revenue guidance for 2023 was significantly revised down from $50 billion to $20 billion due to COVID-related impacts, ultimately yielding just over $12 billion [24][25] - The company anticipates a more stable revenue trajectory moving into 2024, with COVID franchise revenues expected to stabilize around $10 billion [25][26] - Pfizer is tracking well for the current year, although the RSV market has contracted to about 60% of last year's size [28] Cost Management - Pfizer has announced $5.5 billion in cost cuts, with ongoing efforts to optimize costs in R&D, SG&A, and COGS [29][30] - The company is focused on ensuring that investments in new products make economic sense and align with long-term growth strategies [22][30] Product Pipeline and Development - Pfizer is preparing for a significant update on its obesity drug, danuglipron, in Q1 2025, with expectations of competitive weight loss data [11][12][19] - The company is optimistic about its Oncology pipeline, particularly with CDK4/6 inhibitors and other small molecules, which are expected to dominate the market for HR-positive breast cancer [40][44] - Pfizer is exploring the potential of combining its HER2 ADC with PD-1 therapies, anticipating positive outcomes in Phase 3 trials [60][63] Regulatory and Legislative Impact - The company plans to provide guidance for 2025 that includes the impact of the Inflation Reduction Act and Medicare Part D reform, which may have both positive and negative effects on revenue [52][53] - There is an expectation that the reforms will support medication adherence but may also lead to revenue headwinds for high-priced drugs [53][54] Strategic Considerations - Pfizer is evaluating its asset portfolio for potential divestments, particularly in light of its recent acquisition of Seagen and ongoing efforts to improve its balance sheet [56][58] - The company is committed to maximizing shareholder value by focusing on economically viable products and strategic partnerships in R&D [38][58] Management Insights - Andrew Baum highlighted the strengths of Pfizer's medicinal chemistry and execution capabilities, emphasizing the need to focus on products that deliver meaningful economic returns [34][36] - The management team is dedicated to ensuring that the company's powerful resources are directed towards high-value projects that benefit both shareholders and patients [38][39] Additional Insights - The management expressed confidence in the global market potential for obesity treatments, indicating a significant opportunity beyond the U.S. [17][18] - There is a recognition of the competitive landscape in Oncology, with a focus on maintaining a leading position through innovative therapies and strategic development [41][44] This summary encapsulates the key discussions and insights from the Pfizer conference call, highlighting the company's strategic direction, financial outlook, and product development initiatives.

M Update November 19, 2024 01:00 AM GMT | --- | --- | --- | |------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Summary of Key Points from the Conference Call Industry Overview - The U.S. rig count has been on a downward trend since the end of 2022, despite record U.S. oil production and abundant natural gas supply, reflecting the adoption of no or slow growth models from Public Exploration & Production (E&Ps) and significant drilling and completion (D&C) efficiency gains [1][2] - The U.S. land rig count has declined by 5% or 31 rigs on a year-to-date (YTD) basis [1] - Natural gas prices have remained weak, impacting drilling activity, with prices below the marginal cost of supply in most basins since Q2 2023 [1] Rig Count and Activity - The current U.S. land rig count stands at 584, down 8.2% or 52 rigs on a YoY basis [2] - Major operators (Exxon, Chevron, etc.) have increased their active rig count by +22 rigs YTD, while Public E&Ps have dropped -59 rigs [2][31] - The Permian Basin accounts for the most significant number of rig drops YTD, with -15 rigs in the Midland Basin and -3 rigs in the Delaware Basin [33] Basin-Specific Insights - The Haynesville Shale has seen a -29% decline in activity YTD, while the Appalachia rig count fell by -20% [33] - The Williston Basin has experienced a 23% increase in activity YTD, with +7 rigs added [33] Contractor Performance - HP is the most active U.S. drilling contractor with 145 active rigs, followed by PTEN (101 rigs), NBR (64 rigs), ESI (32 rigs), and PD (30 rigs) [2][12] - PD has the highest mix of rigs in natural gas plays at 33%, followed by NBR (17%) and HP (15%) [9] - Among major operators, XOM added 19 rigs reflecting the merger with PXD, while COP and BP added +2 rigs each [31] Public vs. Private Operators - PD is the most levered to Private operators, with 77% of its rigs contracted by Privates, while ESI has 75% of its rigs contracted by Publics [12][16] - Publics/Majors now represent 52% of the horizontal rig count compared to 46% when the Private rig count peaked [2] Rig Type and Direction - Horizontal rigs account for approximately 88% of total rigs in the field today, with a decline of 25 rigs YTD [42] - Public operators have a higher percentage of rigs rated at 1,500hp or greater compared to Privates [43] Conclusion - The U.S. land drilling market is experiencing a significant shift, with a notable decline in rig counts driven by economic factors and operational efficiencies. The performance of contractors varies significantly based on their exposure to public versus private operators and the types of basins they operate in. The ongoing trends suggest a cautious outlook for the industry, particularly in natural gas-focused regions.

SPMI and TE as our preferred plays within this group. See more inside. M | --- | --- | --- | |---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

M Update Investor Presentation | Asia Pacific November 18, 2024 08:00 PM GMT TMT Webcast: The Tech Set-Up into Year-end and Japan SPE S. Korea Technology Asia Pacific Industry View Cautious Greater China Technology Hardware Asia Pacific Industry View In-Line Semiconductor Production Equipment Japan Industry View Attractive Japan Semiconductors Japan Industry View In-Line Morgan Stanley Asia Limited+ Shawn Kim Equity Analyst Shawn.Kim@morganstanley.com +852 3963-1005 Morgan Stanley MUFG Securities Co., Ltd.+ ...

18 November 2024 | 9:01PM GMT EM Equity Strategy 2025 EM Equity Outlook: Domestic reliance amid external risks n Leaning on policy offsets and micro fundamentals amid tough macro. A stronger dollar, higher China and auto tariffs in our baseline forecasts post US elections, and shallower easing cycles in EM, provide a more challenging backdrop for EM equities in 2025. We think EM markets with strong domestic micro fundamentals, that are relatively insulated from external risks and have supportive local polic ...

19 Nov 2024 12:36:35 ET │ 9 pages Global FX Strategy Escalate to de-escalate: increased geopolitics noise until January should still be faded CITI'S TAKE President-elect Trump has made peace negotiations a priority, looking to bring the Russia-Ukraine conflict to a ceasefire and for Israel to quickly conclude operations in Gaza and the broader region. However, that also creates a window before his inauguration where actors involved in these conflicts may try to put themselves in the strongest position ahead ...

North America Equity Research 18 November 2024 J P M O R G A N EE/MI Notes from the Road: Annual EEI Conference Highlights Strong Demand Runway for U.S. Utility/T&D Market Our trip to the annual EEI conference reinforced our confidence in the multi-year favorable outlook for U.S. electric utility spending, and positive view of related exposure in the EE/MI sector (HUBB/ETN/EMR/WCC are most exposed). Increasing expectations on load growth, supported by economic development, now being led by data center deman ...

J P M O R G A N Asia Pacific Equity Research 20 November 2024 This material is neither intended to be distributed to Mainland China investors nor to provide securities investment consultancy services within the territory of Mainland China. This material or any portion hereof may not be reprinted, sold or redistributed without the written consent of J.P. Morgan. China ESS Takeaways from expert call: Strong ESS demand outlook in 2024/25; ESS integration - competitive landscape varies by region but in general ...